Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.

Metastatic Cancer

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Non Chemotherapy

Chemotherapy and target therapy

Chinese herb medicine

Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of medicine

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Clinical Studies by Using Alphacait to Screen Drug Combinations for Advanced Solid Tumor

Progression-free survival (PFS) is defined as the time from assignment in the trial to disease progression or death from any cause.

Defined as the time from assignment to death from any cause.

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response or stable disease to therapy

Drug-related adverse reactions must be recorded, mainly in the following：myelosuppression including neutropenia, anemia and thrombocytopenia;Cardiac toxicity; muscle fatigue, pain, imbalance; Oral ulcers: the patient's gums, cheeks, throat and tongue are prone to ulcers;nausea, vomiting, constipation or diarrhea;hair loss;skin discomfort;hormonal fluctuations, sexual dysfunction, infertility; damage of the kidney;anxiety and depression.

Expectations of exploratory markers for this study include the status of exploratory biomarkers associated with immunohistochemistry (IHC) or quantitative reverse transcription polymerase chain reaction (qRT-PCR), a new generation sequencing method (NGS), Nanostring technique and / or other methods to evaluate archived and/or newly acquired tumor tissue, as well as its association with disease status and/or (Including but not limited to somatic mutations and other exploratory markers) according to qRT-PCR and NGS techniques, and to evaluate the relationship between the therapeutic response, the status of the biomarker during exploratory treatment and during treatment, and the evaluation of plasma, serum or whole blood samples (including but not limited to somatic mutations and other exploratory markers) The association of the above markers with disease status and / or therapeutic response.

Through publication after study completion

Haining Health-Coming Biotech Co., Ltd.

Alphacait, LLC

This single center, open-label, single arm, non-randomized study is designed to evaluate safety, progression-free survival(PFS),overall survival (OS), objective response rate (OPR), and disease control rate (DCR) of chemotherapy or target therapy or chinese medicine based on the Alphacait screening system in subjects with advanced malignant tumor.

500 mg twice daily after meal for 6 weeks

Hyperuricemia

Rhus (Somagh)

Placebo

Shahid Motahhari Clinic, Shiraz University of Medical Sciences

The Effects of Rhus Coriaria L. on Serum Uric Acid Levels

Mesbah Shams, MD

Associate professor of Internal medicine and Endocrinology

Shiraz University of Medical Sciences

Body Weight

500 mg twice daily after meals for 6 weeks

Rhus Coriaria L.(Rhus)

The Effects of Rhus Coriaria L. on Body Weight

The Effects of Rhus Coriaria L. (Rhus or Somagh) on Body Weight

Associate professor of Internal Medicine & Endocrinology

500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks

Placebo capsule: 1 capsule twice daily for 6 weeks

rhus/vėžys

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

The Effects of Rhus Coriaria L. on Serum Uric Acid Levels

The Effects of Rhus Coriaria L. on Body Weight

The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu